Research programme: multiple sclerosis therapeutics - Hard to Treat Diseases

Drug Profile

Research programme: multiple sclerosis therapeutics - Hard to Treat Diseases

Alternative Names: GIFT-15; Ribavirin/tiazofurine; Tiazofurine/ribavirin

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Hard To Treat Diseases
  • Developer Hard To Treat Diseases; Slavica Biochem
  • Class Amides; Glycoproteins; Haematopoietic cell growth factors; Interleukins; Purine nucleosides; Ribonucleosides; Small molecules; Thiazoles
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Serbia
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Canada (IV)
  • 14 Aug 2009 Preclinical trials in Multiple sclerosis in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top